Technology consultancy and investment company Angle says that its portfolio company Geomerics has agreed a corporate partnership with one of the world’s leading technology companies.
The partner will invest up to £2.3m in Geomerics, of which £1m is dependent on milestones being achieved.
Angle currently owns 47% of Geomerics, which has developed software called Enlighten that improves lighting in computer graphics. This deal should still leave Angle with more than 30% of Geomerics.
This latest deal follows news that 25%-owned NeuroTargets’ partner in developing neuropathic pain therapeutic molecules has gained additional finance from Wellcome Trust. The University of Bristol is investigating galanin, which is a protein used by nerve cells to communicate with each other, in order to develop treatments for neuropathic pain. Wellcome Trust has provided a total of £4.3m for this development.
At 29.75p a share, Angle is valued at £8.07m. The Geomerics stake was valued at £2.2m in the accounts for the year to April 2010.
© 2007 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Evolve Capital will hold its requisitioned general meeting on 28 September.
Aim adviser Arden Partners says that tough equity trading conditions mean that it will not meet profit expectations this year.
Zoo Digital says it has gained its first customer for the newly launched range of authoring tools for the electronic sell through market.
IT and software services provider Tikit is confident that trading conditions are starting to improve.
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds